^
Association details:
| Biomarker: | KRAS wild-type |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Findings From an Analysis of Patients With Monocytic and Monocytic‑Like Acute Myeloid Leukemia (AML), Including AML‑M4 and AML‑M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza)
Published date:
09/01/2023
Excerpt:
Patients from Phase Ib M14-358 (NCT02203773) and Phase III VIALE-A (NCT02993523) studies who received Ven+Aza were included….CR+CRi rates (95% CI) were 64% (35.4–84.8) vs 60% (48–71.5) and mOS was 46.3 vs 11.5 months for NPM1mut (n=11) vs wild-type (WT) NPM1 (n=63) mAML, respectively. In N/KRASmut (n=15) vs WT N/KRAS (n=59) mAML, CR+CRi rates (95% CI) were 33% (15.2-58.3) vs 68% (55.1-78.3) and mOS was 3.4 vs 19.4 months, respectively.
Secondary therapy:
azacitidine
